Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Ovarian Cancer Clinical Trial

Official title:

Phase II Clinical Trial on the Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients With Homologous Recombination Deficiency

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03032614
• Other study ID #: CTMS#16-0133
• Secondary ID: 17-166H
• Status: Withdrawn
• Phase: Phase 2
• First received: January 23, 2017
• Last updated: October 6, 2017
• Start date: September 30, 2017
• Est. completion date: April 30, 2020

Study information

• Verified date: August 2017
• Source: The University of Texas Health Science Center at San Antonio
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase II clinical trial of the combination of carboplatin, eribulin, and Veliparib.

Description:

This is a Phase II, non-randomized, open-label, Clinical Trial on the Combination of Carboplatin, Eribulin, and Veliparib in Patients with BRCA-related Cancers.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: April 30, 2020
• Est. primary completion date: March 31, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must have archival biopsy specimens (preferably from metastatic disease) available for research tests. If a suitable biopsy specimen is not available, patients will be asked to undergo a research biopsy to procure tissue

• Patients must be >/= 18 years

• Females of childbearing potential must not have had unprotected sexual intercourse within 30 days prior to study entry and must agree to use a highly effective method of contraception. Females who are using hormonal contraceptives must have been on a stable dose of the same hormonal contraceptive product for at least 4 weeks prior to dosing and must continue to use the same contraceptive during the study and for 30 days after study drug discontinuation

• Patients must have an ECOG performance status 0-1

• Patients may have had a prior diagnosis of cancer if it has been > 5 years since their last treatment for that cancer

• Patients must have normal organ and marrow function as defined below:

• Leukocytes = 3,000/uL

• Absolute neutrophil count = 1,500/uL

• Platelets = 100,000/uL

• Creatinine within normal limits or creatinine clearance =30

• Patients must be able to swallow and retain oral medication

• Patients who were receiving prior systemic therapy: Prior treatment related side effects must have resolved to < Grade 2 severity (except alopecia and infertility)

• All patients must have given signed, informed consent prior to registration on study

• Patients must have stage IV breast or stage III and IV ovarian cancer (including platinum sensitive disease)

• Patients must have BRCA1/2 deleterious mutations, PTEN deficiency, or cancer with a high HRD score as assessed by Myriad's assay

• Patients must have measurable disease per RECIST 1.1 criteria (see above for definition)

• Patients may not have received more than 3 chemotherapeutic regimens for metastatic disease

• Patients may not have received treatment with prior carboplatin, eribulin or a PARP inhibitor

Exclusion Criteria:

• Women who are pregnant or lactating are not eligible

• Patients who are undergoing concomitant radiotherapy are not eligible

• Patients who are receiving any other investigational agents or concurrent anticancer therapy are not eligible

• Previous systemic treatment is allowed with a 21 day washout period prior to registration

• Patients who are taking any herbal (alternative) medicines are not eligible. Patients must be off any such medications by the time of registration

• Patients with known brain metastases are not eligible for participation unless the following are met:

• Brain metastases are treated (either with surgical excision, stereotactic radiosurgery or radiotherapy and have been stable for at least 4 weeks (MRI documented)

• Patient is asymptomatic and has discontinued corticosteroids if taken for that purpose

• Patients with any of the following conditions or complications are NOT eligible for participation:

• GI tract disease resulting in an inability to take oral medication

• Malabsorption syndrome

• Require IV alimentation

• History of prior surgical procedures affecting absorption

• Uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis).

• Hypersensitivity of any of the components of Veliparib, carboplatin, eribulin

• History of significant neurological (no neuropathy > Grade 2) or psychiatric disorders.

• Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis).

• Significant non-neoplastic renal disease.

• Immunocompromised subjects, including subjects known to be infected with human immunodeficiency virus (HIV).

• Uncontrolled endocrine diseases (e.g., diabetes mellitus, hypothyroidism or hyperthyroidism, adrenal disorder) i.e., requiring relevant changes in medication within the last month or hospital admission within the last three months

• Active infection requiring systemic therapy.

• Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, uncontrolled arterial hypertension, unstable angina, myocardial infarction or stroke within 6 months of the first dose of study drug; or cardiac arrhythmia requiring medical treatment.

• Prolongation of QTc interval to > 480 msec when electrolytes balance is normal.

• Major surgery within 4 weeks prior to the first dose of study drug

Related Conditions & MeSH terms

• BRCA1 Mutation
• BRCA2 Mutation
• Breast Cancer Stage IV
• Ovarian Cancer

Intervention

Drug:
• Carboplatin
Carboplatin is a second generation tetravalent organic platinum compound. Similar to cisplatin, carboplatin produces predominantly interstrand DNA crosslinks as opposed to DNA-protein crosslinks. Carboplatin is cell-cycle non-specific.
• Eribulin
Eribulin Mesylate is a synthetic halichondrin analog.
• Veliparib
Veliparib is a potent PARP inhibitor that delays the repair of DNA damage induced by chemotherapeutics.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
The University of Texas Health Science Center at San Antonio

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence, nature and severity of adverse events and serious adverse events, graded according to NCI - Common Toxicity Criteria for Adverse Events version (4.03)	Graded according to NCI - Common Toxicity Criteria for Adverse Events version (4.03)	Approximately 1.5 years
Primary	Tumor response assessed using RECIST 1.1 guidelines	Response will be assessed in this study via physical exam and imaging.	Measured every 6 weeks for 21 day cycles for the duration of study treatment, estimated to be less than one year